For reference, the FDA reviewed Gleevec and Pegasys in four months; Kaletra was approved in 3.5 months. So, even with accelerated approval, 3 weeks is unlikely. Geez, the FDA hasn't even accepted the drug for review and you've already got it approved.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.